Author/Authors :
Hosseini, Mostafa Department of Genetics - Faculty of Biological Sciences - Tarbiat Modares University, Tehran, Iran , Mohammad Soltani, Bahram Department of Genetics - Faculty of Biological Sciences - Tarbiat Modares University, Tehran, Iran , Tavallaei, Mahmoud Human Genetic Research Center - Baqiyatallah University of Medical Sciences, Tehran, Iran , Mowla, Javad Department of Genetics - Faculty of Biological Sciences - Tarbiat Modares University, Tehran, Iran , Tafsiri, Elham Department of Molecular Medicine - Biotechnology Research Center - Pasteur Institute of Iran, Tehran, Iran , Bagheri, Abouzar Department of Clinical Biochemistry and Genetics - Molecular and Cell Biology Research Center - Faculty of Medicine - Mazandaran University of Medical Sciences, Sari, Iran , Khorram Khorshid, Hamid Reza Genetic Research Centre - University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
Abstract :
Background: The cyclin E2 (CYCE2) is an important regulator in the progression and
development of NSCLC, and its ectopic expression promoted the proliferation, invasion,
and migration in several tumors, including Non-Small Cell Lung Cancer
(NSCLC). However, the upregulation of CYCE2 in NSCLC cells suggested that it has a
key role in tumorigenicity. In addition, the RAS family proteins as oncoproteins were
activated in many major tumor types and its suitability as the therapeutic target in
NSCLC was proposed. Considering the crucial role of microRNAs, it was hypothesized
that altered expression of hsa-miR-30d-5p and hsa-let-7b might provide a reliable
diagnostic tumor marker for diagnosis of NSCLC.
Method: Real-time RT-PCR approach could evaluate the expression alteration of
hsa-miR-30d-5p and hsa-let-7b and it was related to the surgically resected tissue of
24 lung cancer patients and 10 non-cancerous patients. The miRNAs expression was
associated with clinicopathological features of the patients.
Results: Hsa-miR-30d showed a significant downregulation (p=0.0382) in resected tissue
of NSCLC patients compared with control group. Its expression level could differentiate
different stages of malignancies from each other. The ROC curve analysis
gave it an AUC=0.73 (p=0.037) which was a good score as a reliable biomarker. In
contrast, hsa-let-7b was significantly overexpressed in tumor samples (p=0.03). Interestingly,
our findings revealed a significant association of hsa-let-7b in adenocarcinoma
tumors, compared to Squamous Cell Carcinomas (SCC) (p<0.05). Also, analysis
of ROC curve of hsa-let-7b (AUC=0.74, p-value=0.042) suggests that it could be
as a suitable biomarker for NSCLC.
Conclusion: Together, these results suggest a possible tumor suppressor role for hsamiR-
30d in lung tumor progression and initiation. Moreover, upregulation of hsa-let-
7b was associated with the tumor type.
